HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $30 price target.
Stocks · News reference
Taiho Oncology And Cullinan Therapeutics Say Results From Planned Interim Analysis Of Phase 3 REZILIENT3 Trial Selected For Presentation In Presidential Symposium 2 At IASLC 2026 World Conference On Lung Cancer
Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLCTaiho
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $39 to $42.